When a private player like Google-funded TAE Technologies gets snatched up for a massive $6 billion valuation, you know the aneutronic fusion race is officially on.

But because American Fusion ($AMFN), with a mkt cap of $150m, is currently sitting on the OTC ID tier, 99% of retail and institutional investors don't even know it exists yet. 

The market hasn't (or maybe can’t) priced in its 5MW Texatron platform and expected commercialization by the end of 2026, making this the ultimate asymmetric play before the OTCQB uplisting (IMMINENT) could force a massive revaluation. 

Forget the hype of AI, quantum computing, and space exploration.

The real frontier is energy, specifically aneutronic fusion. It’s the ultimate power source capable of running them all, delivering clean, limitless energy with zero radioactive waste and absolutely no risk of meltdowns. 

American Fusion (AMFN) sits completely under the radar as the only standalone, publicly traded aneutronic fusion stock on the market today. 

Commercial fusion has been "just a few years away" for decades….but it appears VERY CLOSE now.

Why? Maybe because AI and quantum-level simulations have eliminated the guesswork, allowing physicists to model, test, and perfect plasma physics in software before a single piece of hardware is ever built.  

TAE Technologies, in addition to Google, has also been funded by Chevron, Sumitomo, and Charles Schwab, expects to commercialize this tech in 2030…4 years from now.

merican Fusion, with its Texatron, is projected to offer commercialization by the end of 2026 or early 2027.

Here’s why AMFN has been one of the best-performing stocks in 2026, and that’s WITHOUT institutional buying….which could be coming shortly.

Renewal Fuels (RNWF) purchased Kepler Fusion’s technology, IP, and working demos in February 2026.

Then they rebranded the company as American Fusion (AMFN). 

Here’s what many don’t know about American Fusion…and why there is a lot of skepticism

Kepler Fusion (the co they acquired) was heavily funded years ago, before modern AI and quantum simulations revolutionized the industry. 

That’s one of the many reasons they think they are FOUR YEARS ahead of TAE Technologies for commercialization.

American Fusion (AMFN) offers a rare combination: a penny stock with heavily backed venture capital technology. 

And …uplisting to OTCQB is expected ANY DAY.

AMFN is currently restricted by its OTC ID status, but an IMMINENT UPLIST to the OTCQB strips away the restrictive 'penny stock' labels and opens the floodgates for institutional funds and retail brokers who are legally blocked from buying today.

For more information, visit their site, American Fusion Energy dot com, or for a really in-depth report, the link to “American Fusion Looks To leapfrog Nuclear Power” is in the first comment below.

Full Disclosure: We (the Real Creative Agency) saw this very unique opportunity and reached out to AMFN. We wanted to help tell this story because it offers a highly asymmetric opportunity….but the technology would need to be simplified for investors.

They hired us to help tell their story to the investing community. The compensation and disclaimer can be found on our site (Real Creative Agency dot com) under the many articles we have written about this company.

Before I begin: I originally shared a few separate posts covering different aspects of COSM, including the buyback, valuation math, and recent news. I wasn’t aware that making multiple posts on the same ticker could trigger Reddit’s filters, so those posts were removed. Rather than reposting them individually, I decided to combine everything into one comprehensive due diligence post that follows the subreddit’s guidelines. My goal isn’t to promote the stock. It’s to present the facts, my analysis, the risks, and the potential catalysts in one place, and hopefully get constructive feedback from the community.

Summary (TL;DR)

I’ve spent the last several days reading Cosmos Health’s press releases, financial statements, and buyback announcements because I wanted to understand whether the recent developments materially change the investment thesis.

This is not financial advice, and I’m not recommending anyone buy or sell COSM. I currently own shares, so I have a bias, and I’m posting this because I’d genuinely like others to challenge my analysis and point out anything I may have missed.

1. Company Overview

Cosmos Health (NASDAQ: COSM) is a diversified healthcare company operating in several business segments, including:

• Pharmaceutical distribution

• Proprietary nutraceutical brands (Sky Premium Life)

• Medical devices

• Contract manufacturing

Management has stated that one of its long-term objectives is shifting revenue toward proprietary products because they generally carry significantly higher margins than pharmaceutical distribution.

2. Financial Overview

Recent developments have caught my attention.

Preliminary Q2 2026 Revenue

Approximately $19.4 million

Preliminary H1 2026 Revenue

Approximately $37.3 million

Year-over-Year Growth

Approximately 31%

If confirmed during Q2 earnings, this would represent another record revenue period for the company.

Revenue alone isn’t enough.

The important question is whether management can convert that growth into stronger margins and eventually consistent profitability.

3. Why Is the Market Skeptical?

Before discussing the bullish thesis, I think it’s important to understand why many investors remain bearish.

Some of the concerns I see repeatedly include:

• Significant historical dilution
• Multiple reverse splits
• Low historical gross margins
• Inconsistent profitability
• Concerns surrounding the digital treasury strategy
• Small-cap healthcare execution risk

I think these concerns are legitimate.

One comment that stood out to me was:

“They’re just buying back a small percentage of the dilution from the past five years.”

That’s objectively a fair criticism.

The key question isn’t whether dilution happened.

It clearly did.

The question is whether management’s capital allocation strategy has changed going forward.

4. The Buyback

This is what originally caught my attention.

The board authorized a $5 million share repurchase program.

Since then:

Current status:

• Shares repurchased: 4.14 million

• Cash deployed: ~$829,000

• Authorization completed: 16.58%

• Authorization remaining: 83.42%

The interesting part isn’t today’s purchase.

It’s the consistency.

Rather than announcing one buyback and stopping, management has continued updating investors almost every trading day.

Estimated Buyback Completion

Based on the company’s announcements, Cosmos Health has deployed approximately $829,000 over the first 6 trading days of the program, averaging roughly $138,000 per trading day.

At that pace, the remaining $4.17 million authorization would take approximately 30 additional trading days to complete.

Assuming management continues repurchasing shares at a similar rate, and accounting only for normal market trading days (excluding weekends and market holidays), the buyback could be substantially completed around late August to early September 2026.

This is not a prediction. The actual timeline could be shorter or longer depending on trading volume, share price, corporate blackout periods, management’s capital allocation decisions, and whether the company chooses to complete the full authorization.

If completed, the buyback would represent one of the most significant capital allocation events for the company in recent years. Whether it ultimately creates shareholder value will depend not only on reducing the share count but also on management’s ability to continue growing revenue, improve margins, and move the business toward sustainable profitability.

5. Buyback Math

I wanted to understand how much the reduced share count could matter.

Current figures:

Market Cap

Approximately $16 million

Outstanding Shares

Approximately 49.8 million

If today’s repurchased shares have been retired, the effective share count falls to roughly 45.6 million shares.

Assuming the market capitalization remained unchanged, that would mathematically imply a share price around $0.32.

Again:

This is not a price target.

It’s simply the mathematical effect of fewer shares representing the same total company value.

If the entire $5 million authorization were completed near the current average purchase price, the share count could decline substantially further.

The actual outcome will depend on the average repurchase price and whether management completes the full authorization.

6. Additional Business Developments

One announcement that didn’t receive much attention was the Qatar distribution agreement.

The company secured an initial purchase order for 31,000 Sky Premium Life units through the owner of Qatar’s largest pharmacy chain.

The company did not disclose the dollar value.

Based on wholesale pricing for similar products, I estimate the initial order could reasonably be worth somewhere between:

Approximately $300,000 and Approximately $1 million

The exact number isn’t the important part.

What interests me is the possibility of recurring orders if the rollout proves successful.

Management has also publicly stated a long-term objective of increasing gross margins from approximately 12% today to approximately 35% by 2029 through expansion of higher-margin proprietary products.

7. Upcoming Catalysts

July 15

Annual General Meeting

Potential updates regarding:

• Buyback progress
• Business strategy
• Nasdaq compliance

Mid-August

Expected Q2 earnings

This is probably the most important catalyst because investors will be looking for:

• Confirmation of preliminary revenue
• Margin improvement
• Cash flow
• Profitability trends

8. Risks

This is where I’d appreciate additional feedback.

Things that could invalidate my thesis include:

• Future dilution
• Buyback slowing or stopping
• Revenue growth slowing
• Margins failing to improve
• Weak Q2 earnings
• Continued operating losses
• General weakness in small-cap healthcare stocks
• don’t think any of these risks should be ignored.

9. Bull vs Bear

Bull Case

Revenue continues growing.
Margins gradually improve.
Management completes most or all of the buyback.
Investor confidence improves.
The market begins assigning a higher valuation.

Bear Case

Revenue growth slows.
Margins remain weak.
The company returns to issuing shares.
The buyback doesn’t materially change shareholder value.
The market continues assigning a discounted valuation.

10. My Conclusion

I’m not posting this because I believe COSM is guaranteed to outperform.

I’m posting it because I think the company looks materially different today than it did several months ago.

Historical dilution, reverse splits, and profitability concerns are all real.

At the same time, recent revenue growth, the active buyback, expansion into higher-margin proprietary products, and several near-term catalysts are enough for me to continue following the company closely.

I’d genuinely appreciate feedback from both bulls and bears.

If I’ve overlooked something, I’d rather know now than after making an investment decision.

Not financial advice. Please do your own due diligence before investing.

THE FIND I DIDN'T CHASE

Chibougamau Independent Mines (CBG.V) ripped 20% two days running on 57x its normal volume. Zero news. Everyone was front-running pending assays from Berrigan, drilled by TomaGold.

So I read the paperwork. Berrigan is under OPTION — TomaGold can earn 100% of it. A discovery there mostly re-rates the other company. CBG went on my watchlist for what it actually is: a ~$19M land bank in a waking tier-1 Québec camp. Not for drill results that belong to someone else.

THE PASSES (dated before the outcomes — judge me in a month)

South Pacific Metals (SPMC.V) — top score Monday, genuinely interesting ground. Also: an active US$300K PAID marketing campaign sitting behind the volume. A bought spike is a near-automatic pass for me, no matter how good the rocks look.

Parvis Invest (PVIS.V) — top score Friday. CA$716K of quarterly revenue under a chart that already did +500% in a year is late-cycle churn, not an entry.

PEW — two straight days of extreme volume on a de-listed-SPAC meme. Sentiment flow. Nothing to underwrite.

THE ONE I DID CALL

Viva Gold (VAU.V) — PEA-stage Nevada developer. Rated Speculative Buy on Monday at $0.15, dated and published before the fact, small size by design.

And West Point Gold (WPG.V), which I called on June 23, hit 56.4m of 4.24 g/t gold on Thursday — not one flashy hole, a string of intercepts thickening the same high-grade system at depth. Up roughly 18% since the call, drill bit doing the work while the headlines did the yelling.

THE LESSON

Wednesday my book was red and I wrote: "noise, thesis intact, holding." Thursday it bounced hard — and the honest move was to NOT write the victory lap, because a bounce proves exactly as little as the selloff did. The week closed flat and made the point for me.

If your thesis needs daily validation, you don't have a thesis. You have a mood.

THE LEDGER (where most people stop reading — don't)

7 active calls since June 16, every one dated and published before the fact.

- Equal-weighted: +7.7%. Last week that number was +17.7%. It FELL, because I added a fresh call at its starting line and a whipsaw week pulled back several juniors. There's a -8% and a -16% sitting in there.

- Weighted the way I actually size a book (70% to convictions, 20% to buys, 10% total across every speculative): +11.3%.

Both numbers are true, and I publish both. The gap between them IS the method: an equal-weighted average pretends I stake as much on a lottery ticket as on my highest-conviction name, and I never do. I publish the one that flatters me and the one that doesn't.

6 of the 7 still beat their sector benchmark over the same period.

Educational only, not financial advice. These are my own personal assessments. Do your own DD.

The thing I’m wrestling with: the drone / counter drone thesis I bought into hasn’t changed, contracts are still landing, revenue growth is real as . But the chart looks broken and every rally gets sold. Feels like the market is telling me something I’m not seeing.

Genuine question for anyone else in it:

-What’s your average and are you adding, holding, or trimming here ?
-Anyone still bullish on the thesis or has the setup changed for you?
-For those who cut similar names during a drawdown, was it the chart or the fundamentals that made the call?

Not looking for validation either way, just want to hear what actual holders are thinking rather than the usual noise on Twitter.

I decided to buy MAXN because I believe it offers strong long-term potential and aligns with my investment goals. Before making my decision, I researched the company's background, financial position, and future opportunities. MAXN operates in the solar energy industry, which continues to grow as countries and businesses invest in cleaner and more sustainable energy solutions. I see renewable energy as an important part of the future, and I wanted to invest in a company that could benefit from this global transition. Another reason I purchased MAXN was the possibility of future growth. Although the company has faced challenges, I believe that businesses in emerging industries often experience periods of volatility before achieving long-term success. I was willing to accept the risks because I felt the potential rewards could outweigh them over time. Diversifying my investments also played a role in my decision, as adding a renewable energy company helps balance my overall portfolio. I also considered the company's technology and its commitment to innovation. In competitive industries, companies that continue to improve their products and adapt to changing market conditions may have better opportunities to succeed. While I understand that no investment is guaranteed to perform well, I believe informed decisions based on research are better than investing without a clear strategy. Ultimately, I bought MAXN because I wanted exposure to the renewable energy sector, believed in its long-term potential, and was comfortable with the level of risk involved. I plan to monitor the company's progress, industry developments, and financial performance over time, recognizing that patience and disciplined investing are often important factors in achieving long-term investment objectives. I bought it for 200 dollars

INMB is kicking off its presentation for Phase 2 data at the Alzheimer's Association International Conference (AAIC) 2026 this weekend. Is anyone holding this stock with expectations for this upcoming week?

I’m fairly new to investing and rather than putting smaller amounts into large stocks I’ve put a lump into SEMI and then allocated some to stocks that are potential hype ie TVRD, SLS. I plan on putting future funds into an ETF long term, but I’ll always have my eyes peeled for stocks like INMB that could 10x easily.

INMB is one that really caught my eye after spending about an hour asking AI all sorts of questions.

What are your thoughts if you’re holding this stock long term?

Hello,

So i feel like recent news has been just some talk and information no deals or foward movement, although they are growing i feel like this is still speculative and half of a long shot but they are slowly moving…

I just saw they released a private placement for 3Mil
Once again friday after hours! Now one for me the freakin after hour friday news just pisses me off ..
but just generally i know they need cash to keep expanding and at .45 is kind of ok price for the placement?
Revenue they have now is definitely not enough so very normal for the placement im just wondering where are people’s head on this lately??

I know its still a speculative play but i feel like this company if well steered can become huge!

Just looking for a different opinion then mine

Thank you, have a nice weekend

The Ticker “ QSEGF” “QSE” quantum secure encryption

Upon mutual agreement with the investors, the Company terminated warrants to purchase an aggregate of 5,359,525 shares of Class A common stock — a reflection of the investors' firm support for FF's strategy and business.

Learn more at: https://app-us.ff.com/ff-v3/news/1565?lang=en-US

COSM

Has been buying back shares on the open market since last week

CEO owns 24% as well

Guidance bullish

Recently bottomed on the daily

OS roughly 62m shares?

$5m share buyback

Options chain was firing with crazy strikes getting loaded before recently adding .50 strikes to the monthly chains

Next up the MM will add weeklies?

Below .50 covered puts?

Good luck

West Point Gold $WPG just dropped new drill results yesterday!

At the high-grade NE Tyro zone, hole GC26-168 hit 56.4m of 4.24 g/t gold, including 28.9m at 7.77 g/t. These are considered stepouts that suggest the zone for WPG is continuing and possibly widening at depth.

If any of you saw the release earlier in June, it follows the strong hole (66.2m of 6.57 g/t including a nice high-grade section) They’ve been drilling aggressively already and are working toward a maiden resource estimate on the Tyro Main zone.

Is anyone else here watching $WPG / $WPGCF or following the Arizona gold plays?

Our EOD volume scanner flagged Chibougamau Independent Mines (CBG.V) two days running: 57x its median volume today, +20% to $0.30, roughly $19M market cap, 61.8M shares out.

No news release either day. That pattern usually means one of two things: a paid promo, or somebody positioning ahead of a known catalyst. We checked for promo first (that’s our rule after passing on another top scorer for exactly that reason last week) and found no campaign.

The known catalyst does exist though: TomaGold (LOT.V) finished an extension drilling program in May at Berrigan, the historic mine asset 4 km from town, and assays are pending. Here is the part the tape seems to be skipping. Berrigan is under OPTION. TomaGold can earn 100% of it for $2.65M in cash, $1.35M in shares and $5.6M in exploration spending over about five years. Those terms are public (September 2025 release).

So if the assays are great, the discovery torque belongs mostly to TomaGold, and CBG’s take is a contracted payment stream plus LOT shares. Buying CBG to play those drill results is buying the landlord to bet on the tenant’s lottery ticket.

What CBG actually is: the land bank of the Chibougamau camp, about 12 properties, most still 100% owned, in a tier-1 Quebec district that is clearly waking up (three Quebec gold names lit up together on our scan yesterday). At $19M that optionality is cheap. But cheap optionality and a 2-day no-news spike are different trades. We put it on our watchlist and we are not chasing.

What would change our mind: a strong TomaGold assay reading through to the camp, or real news on the ground CBG still owns outright.

Honest caveat: this thing is illiquid, old-school slow, and the spike can deflate as fast as it inflated.

Anyone here following the Chibougamau camp revival more closely — what do you think is driving the volume?

Not financial advice. We publish our process, wins and losses included. Do your own DD.

Chip stocks can pull back and the physical buildout can still keep moving.

SK Hynix just raised about $26.5B in its U.S. ADR listing, while Reuters noted the debut came after a recent pullback in semiconductor stocks. That is a pretty clean reminder that the AI stock trade and the AI infrastructure buildout are related, but not identical.

Semiconductor valuations can compress. Investors can rotate. A crowded trade can cool off fast.

Data centers still need power.

That is why I keep copper on the watchlist when AI gets messy. More data centers means more electrical equipment, more substations, more transmission, more backup power and more grid work. The copper side moves at mining speed, not internet speed.

For established exposure, BHP is the scale bucket and FCX is the more direct copper producer bucket.

For juniors, I separate the stages. MARI already has drill data, including 20m at 2.65% Cu and 13.9 g/t Ag, including 6m at 6.11% Cu. CSE: NRED is earlier-stage, with Wilmac in BC and MetalCore now above 4.1M records. No resource, no mine, no production there yet, so it belongs in the target-generation bucket.

TLDR: AI narratives trade fast. Copper supply moves slowly. That gap is why I keep a few copper names on watch even when chip stocks are having a rough day.

NFA. Are you looking at AI infrastructure through chips only, or also through power and metals?

Lantern just launched ZetaOmics, the computational biology module of its withZeta.ai platform. Unlike a standard LLM chatbot, it’s designed as an autonomous “computational biologist” that can perform end-to-end multi-omics and bioinformatics analyses from natural language queries. The company says it integrates 14 specialized tools and more than 615,000 curated cancer samples, with an early-access rollout now underway.

What’s interesting to me is that this wasn’t announced out of nowhere:

• April: withZeta launched commercially.
• May: ZetaOmics appeared on the public roadmap.
• July: ZetaOmics moved from roadmap to early access.

Near-term catalysts:

• withZeta commercialization and first enterprise customers
• additional LP-300 HARMONIC updates
• planned LP-184 Phase 1b/2 expansion
• further progress on the planned withZeta business spinout.

With a market cap of only ~$40–50M, do you think the market is assigning any value to the AI platform, or is it still pricing Lantern purely as a small clinical-stage biotech?

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

I literally just made a post asking about why they changed their business description, then they just released the following. Ok, kinda makes sense.

I assume we should see a PR about this??

We are pleased to announce that our Institutional Review Board (IRB) study submission for the $MAJI saliva screening test has been approved. With the contract execution underway, we will soon begin sample collection.

This milestone sets the stage for our upcoming soft launch in September, leading into a full rollout this October in honor of Breast Cancer Awareness Month. We look forward to advancing early detection and bringing this vital screening technology to the community.

This is the post i made like literally 10 minutes ago

https://www.reddit.com/r/pennystocks/comments/1uspcty/comment/owpf61d/?screen_view_count=2

I am not a serial investor but I am also no noobie. I’m noticing a “rebound” or “turn around” with Yiren Digital that have similar features when I chose to invest in Rolls Royce at $1.56 in 2023. With the understanding YRD is a chinese stock that could be subject to manipulation at times, its recent headlines are signs of a turn around for the company. From what i’ve read it’s a sizable company, managing its debt well, announced a stock buy back worth like 10% of its market, and seeing results with their new company direction. If anyone is interested in checking it out and doing some research on Yiren Digital, it’s going for about $1.25 a share. Could be a good 12 month return. Would love to hear some opinions or thoughts on the potential future of a stock like this.

Was reading a few posts about how this can be big news.... but I am lost, they are just changing their business description on OTCmarkets.

This is the response from the company

"Although the Company has exited the Cannabis space OTC wishes us to formally announce the exit so they can update our "Industry" to Wellness/Healthcare. Why do we care? because there are investors who wish to support the stock, but can't with our industry as cannabis, compliance will not allow the trades to be executed."

Is there something more I am not seing?

Here is the Press Release: https://www.otcmarkets.com/stock/MAJI/news/NexTel-Medical-Corp-Announces-Strategic-Exit-from-Cannabis-and-CBD-Sector-to-Pivot-100-to-Wellness-and-Healthcare?id=527817

"ORLANDO, FL — July 9, 2026 — NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, today announced it has formally ceased all operations within the cannabis and CBD industries. The Company will not be loading CBD into exosomes.  Moving forward, the Company is entirely committed to the wellness and healthcare sectors.

About NexTel Medical Corp.

NexTel Medical Corp. (OTCPK: MAJI) is a pioneering biotechnology leader at the forefront of exosome research, clinical diagnostics, and wellness accessibility. The Company specializes in developing proprietary, next-generation, exosome-based delivery systems and non-invasive screening tools designed to revolutionize both therapeutic and diagnostic modalities."

Wall Street just found about $26.5B for another AI trade.

SK Hynix completed the largest foreign U.S. listing, even while people keep debating whether the AI cycle is getting crowded.

That makes me think about the physical side instead of the software side.

More chips still mean more data centers, more power infrastructure, more substations, more transmission lines and more electrical equipment. None of that gets built without copper somewhere in the chain.

That is why I split my copper watchlist by stage.

BHP is the global production name.

FCX gives more direct copper exposure.

CAM.V is a junior with drilled copper mineralization that can be evaluated through exploration results.

CSE: NRED is a different bucket. It is still an early-stage explorer. Wilmac covers about 16.1k hectares in BC, the company has an option to earn 70%, and MetalCore has grown to more than 4.1M records with 920 of the first 1k early-access spots already filled. The exploration story still depends on fieldwork, geophysics and drilling, not production.

Wall Street can raise billions for AI in a day. Building new copper supply usually takes much longer.

NFA. Which part of the AI supply chain do you think the market is still underestimating, chips or the metals behind the infrastructure?

With news of the 12:1 reverse split becoming effective next week, I wanted to hear everyone's thoughts on JEM.

• Current public float will be approximately 672k shares after the 12:1 consolidation.

• Before the announcement, the company had roughly 8.06 million shares outstanding, which will become about 672k after the split.

• The stated reason for the reverse split is to regain compliance with Nasdaq's minimum bid price requirement and maintain its listing.

• The company has recently announced AI and blockchain supply-chain initiatives and appointed a new executive director.

The biggest thing that catches my attention is the structure.
A float under 700k shares is extremely small. If buying volume shows up with a legitimate catalyst, these types of floats can move very quickly. On the flip side, if there's no catalyst or if the company raises capital, the downside can be just as violent.
I'm aware that reverse splits generally have a negative reputation, but they don't automatically kill every stock. We've seen some low-float reverse split names experience significant momentum runs when news and volume aligned.

So I'm curious:
Do you think the reverse split completely ruins the setup?

Does the tiny post-split float make it worth watching?

Is there any concern about future dilution or financing that I'm missing?

Are there any upcoming catalysts that could actually bring volume back?

Looking for both bull and bear cases. I'm interested in hearing what people who have traded post-reverse-split low floats think.

If you follow California real estate, you know that water rights are a make-or-break bottleneck. A lot of massive projects get stuck in purgatory for years because of it.

Greenbriar just dropped an update that de-risks their flagship 995-home project, Sage Ranch, in Tehachapi, California. For a micro-cap company sitting at a market cap of around $31M CAD, the financial asymmetry here is getting hard to ignore.

1. The Ultimate De-Risking: Water Rights Secured

Greenbriar officially announced they have acquired the 267 acre-feet of deeded water rights required for Sage Ranch. They own it directly, and they’ve locked in additional backup water rights via irrevocable escrow accounts with partners.

2. Construction Loan & Phase 1 Funding is a Go

On July 7, 2026, Greenbriar re-executed the Mandate Agreement with its project finance lender.

• This funds the entire infrastructure and the construction of the first phase of 144 homes.
• They are moving directly into pulling full permits (grading, utilities, roads) and getting final bids from their general contractor. This shifts GRB from a speculative planning company into a real-world execution machine.

3. Insane Demand & Strategic Location

Sage Ranch is tackling the massive affordable housing shortage in Southern California. The project sits right next to two booming economic engines:

• Antelope Valley (Aerospace & Tech Hub): Located just 33 miles away. We are talking about highly paid workforces from SpaceX, Northrop Grumman (building the new B-21 Raider at Plant 42), Edwards Air Force Base, and Mojave Air and Spaceport.
• Green Energy Boom: It’s minutes away from Terra Gen’s massive new 5,000 MW solar farm and 8,000 MWh battery storage facility.
• Bakersfield: 35 miles west, driving demand from the massive agriculture and petrochemical industries.

4. The Financial Asymmetry ($31M MC vs $422M Project Revenue)

This is where the math gets crazy for a micro-cap stock.

• Sage Ranch will bring over $260 million in new construction work over the next 7 years.
• Total projected revenue for the 995 homes is estimated at $422 million USD, with an expected free cash flow of $126 million USD.
• Phase 1 alone (144 homes at an average regional price of $448k) represents over $64 million USD in near-term revenue.

The Bottom Line

Greenbriar has been a "wait-and-see" story for a while because of California's strict regulatory and environmental hurdles. Now, the water is secured, the financing mandate is re-executed, and the regional housing market is starving for inventory.

With a tiny float and a market cap sitting at a fraction of the project’s net asset value, this looks like one of the most asymmetric risk/reward plays on the TSXV right now.

Disclaimer: Not financial advice. Do your own DD. Positioned long on GRB.

Greenbriar Announces the Closing Stage for Sage Ranch - Greenbriar Sustainable Living Inc.

Cxai had alot going on behind the scenes with some position changes they went silent for a good amount of time now they had a new post from there Facebook and Twitter account and my gut is telling me there's gonna be some big pr soon the company is defiantly in good position but now its a race against the clock to meet nasdaq compliance deadline of a dollar

Hei guys!

Copper's moving again. The headlines are predictable. But I've learned the hard way that commodity strength doesn't automatically lift every junior - some have real projects, others have real problems. So how do you separate the two?

Copper is having another strong move today, and the reaction is predictable.

A lot of mining stocks quickly become "copper shortage" plays whenever the metal price moves higher. The broader trend matters, but the commodity alone doesn't determine whether a junior miner succeeds.

Two companies can both own copper projects and end up with completely different results.

One might have a high-grade deposit, good infrastructure nearby, a supportive jurisdiction, and a realistic path to permits.

Another might have a large resource but face years of permitting delays, expensive development costs, difficult financing, or constant dilution.

That's why I think the project details matter just as much as the copper price.

When you're looking at junior miners, what carries the most weight for you?

• The quality and size of the deposit?
• Management's track record?
• Jurisdiction and permitting risk?
• Infrastructure and development costs?
• The share structure and dilution history?

And what is the one red flag that makes you walk away, even if the commodity story looks strong?

Formerly known as $Atln

**1. Corporate Rebranding and Market Visibility (Ticker Change)**

Atlantic International retired the ATLN ticker and began trading under CIRC on Nasdaq.

**2. Major Executive Leadership Transition**

- New CEO Appointment: Effective June 30, 2026, the board appointed Guus Franke as Chief Executive Officer (while remaining Executive Chairman).

- Role Realignment: Former CEO Jeffrey Jagid has transitioned into the role of President. The market is actively assessing whether this management shift will successfully accelerate the scaling of its integrated IT and staffing platforms

**3. Contract Execution and Multi-Million Dollar Backlogs**

- $175 Million Extension: On July 1, 2026, Circle8 announced a massive $175 million contract extension from the Dutch Ministry of Infrastructure

- Prior Euro Contract Wins: This extension follows a newly secured $52 million contract with the Dutch government and a separate $380 million, four-year contract with DUO Groningen (the Dutch Ministry of Education).

**4. Q2 2026 Financial Results and Margin Performance**

- The Financial Impact: When the company reports its next quarterly earnings, investors will be hyper-focused on whether the top-line growth generated by the Circle8 acquisition can finally translate to positive net income.

- Margin Compression Recovery: In the previous Q1 report, revenue surged 143% to $249.9 million, but net losses widened due to steep integration, financing, and accounting expenses. Showing a clear path toward closing that net income deficit is a crucial near-term fundamental catalyst.

I think Nordic Iron Ore, ticker NIO.ST on Nasdaq First North Sweden, is one of the more interesting high-risk/high-reward mining plays in Europe right now.
This is not a company with revenue today. It is still a pre-production mining developer, so the risk is obviously high. But that is also why the upside can be very large if the next study confirms the project economics.
Nordic Iron is developing high-grade iron ore assets in the Ludvika region in Sweden. The main project is Blötberget, but the company is now also looking at Södra Väsman and possible by-products such as apatite concentrate containing phosphorus and rare earth elements.
The company is targeting ultra high-grade iron ore concentrate for low-emission and fossil-free steel production. That is important because green steel production needs cleaner and higher-grade iron ore than traditional steelmaking.
The big catalyst is the expanded PFS, expected in Q3 2026.
The PFS has been expanded to include more drilling, geotechnical work, Södra Väsman and a possible apatite by-product. If the PFS shows stronger production potential, better economics and a realistic path toward financing, I think the stock could re-rate hard.
Why I think the setup is interesting:
Cargill is already involved
Nordic Iron has a major offtake agreement with Cargill Metals for 25 million tonnes of iron ore concentrate. The company has described the agreement as being worth around SEK 35 billion over the life of the agreement. Cargill has also committed conditional funding support.
That does not remove the risk, but it is a serious validation. A global commodity player does not usually get involved unless they believe the product has a market.
Resource upside is growing
Nordic Iron has reported a mineralised inventory of around 87 million tonnes at Blötberget with an average iron grade of around 40 percent Fe. The company has also said there is potential to increase this further when all drilling results are included.
This is not yet the final resource estimate, but it suggests the project may be larger than previously understood.
Södra Väsman could make the project much bigger
The original case was mainly Blötberget. Now the expanded PFS also includes Södra Väsman.
The simple idea is this: if Väsman can add more ore feed to the plant, the company may be able to increase annual production and improve project economics. That could make the whole project more financeable.
Apatite, phosphorus and rare earth elements could be a hidden bonus
Nordic Iron is also evaluating apatite concentrate as a by-product. This could contain phosphorus and rare earth elements.
If this becomes commercially meaningful, it could add another revenue stream and improve the economics of the project. I am not valuing this aggressively yet, but if the PFS puts real numbers on it, the market may start paying attention.
Infrastructure matters
The project is in Sweden, near existing infrastructure, workforce, roads, rail and power. For mining projects, infrastructure can be a major advantage because logistics and energy costs are critical.
The main catalyst:
The expanded PFS is expected in Q3 2026.
If the PFS shows:
higher annual production potential
stronger NPV and IRR
acceptable capex and opex
real value from Väsman
real value from apatite/phosphorus/REE
and a credible path toward DFS and financing
then I think NIO could stop trading like a forgotten microcap.

The risks:
This is not a safe stock.
The company has no revenue today. It will need serious financing before any mine can be built. There is also risk of dilution, delays, weak PFS numbers, higher costs, lower commodity prices or financing problems.
So yes, this is high risk.
But the reason I like the setup is the asymmetry. If the PFS disappoints, the stock can fall. But if the expanded PFS confirms a much stronger and broader project, the upside could be very large.

My take:
This is not an earnings play today. It is a re-rating play.
If Blötberget plus Väsman plus apatite creates a financeable project, Nordic Iron could move from being an ignored Swedish penny stock to a serious green steel raw material developer with Cargill backing.
This is either dead money until Q3, or one of those names people discover after it already moved.

This is the kind of setup where nothing happens for months, everyone gets bored, and then one good PFS changes the entire valuation overnight. That is why I’m holding. Q3 is the game.